

Amendments to the Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1-36. (canceled)

37. (currently amended) A composition of matter comprising as an admixture at least one compound selected from group (i) and at least one compound selected from group (ii),

wherein group (i) consists of:

Group a) consisting of:


tramadol, O-demethyltramadol or O-demethyl-N-mono-demethyl-tramadol,

Group b) consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (~~meperidine~~)
- tilidine
- tramadol
- viminal
- butorphanol
- dextromoramide
- dezocine
- diacetylmorphine (~~heroin~~)

- hydrocodone
- hydromorphone
- ketobemidone
- levomethadone
- levomethadyl-acetate-(1- α -acetylmethadol) (LAAM)
- levorphanol
- morphine
- nalorphine
- oxycodone
- pentazocine
- piritramide
- alfentanil
- buprenorphine
- etorphine
- fentanyl
- remifentanil
- sufentanil

Group c) consisting of: 1-phenyl-3-dimethylamino-propane compounds
corresponding to formula I



wherein

X is ~~chosen from~~ OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from
C₁₋₃-alkyl, branched or unbranched, saturated or unsaturated,
unsubstituted or mono- or polysubstituted,

R¹ is chosen from C₁₋₄-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

R² and R³ in each case independently of one another are chosen from H or C₁₋₄-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, or


R² and R³ together form a saturated C₄₋₇-cycloalkyl radical, unsubstituted or mono- or polysubstituted,

R⁹ to R¹³ in each case independently of one another are chosen from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R¹⁷ and R¹⁸ in each case independently of one another are chosen from H; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or

R⁹ and R¹⁰ or R¹⁰ and R¹¹ together form an OCH₂O, OCH₂CH₂O, OCH=CH, CH=CHO, CH=C(CH₃)O, OC(CH₃)=CH, (CH₂)₄ or OCH=CHO ring,

Group d) consisting of substituted 6-dimethylaminomethyl-1-phenylcyclohexane compounds corresponding to formula II



II

wherein

X is ~~chosen from~~ OH, F, Cl, H or OC(O)R⁷, where R⁷ is chosen from C₁₋₃-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

R¹ is ~~chosen from~~ C₁₋₄-alkyl, benzyl, CF₃, OH, OCH₂-C₆H₅, O-C₁₋₄-alkyl, Cl or F and


R⁹ to R¹³ in each case independently of one another are chosen from H, F, Cl, Br, I, CH₂F, CHF₂, CF₃, OH, SH, OR¹⁴, OCF₃, SR¹⁴, NR¹⁷R¹⁸, SOCH₃, SOCF₃; SO₂CH₃, SO₂CF₃, CN, COOR¹⁴, NO₂, CONR¹⁷R¹⁸; C₁₋₆-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R¹⁴ is chosen from C₁₋₆-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C₁₋₄-alkyl)₂, CO(OC₁₋₅-alkyl), CONH-C₆H₄-(C₁₋₃-alkyl), CO(C₁₋₅-alkyl), CO-CHR¹⁷-NHR¹⁸, CO-C₆H₄-R¹⁵, where R¹⁵ is ortho-OCOC₁₋₃-alkyl or meta- or para-CH₂N(R¹⁶)₂ where R¹⁶ is C₁₋₄-alkyl or 4-morpholino, wherein in the radicals R¹⁴, R¹⁵ and R¹⁶ the alkyl

groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R^{17} and R^{18} in each case independently of one another are chosen from the group consisting of H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or

R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

Group e) consisting of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds corresponding to formula III



III

wherein

X is ~~chosen from~~ OH, F, Cl, H or $OC(O)R^7$, where R^7 is chosen from C_{1-3} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, and

R^9 to R^{13} in each case independently of one another are chosen from H, F, Cl, Br, I, CH_2F , CHF_2 , CF_3 , OH, SH, OR^{14} , OCF_3 , SR^{14} , $NR^{17}R^{18}$, $SOCH_3$, $SOCF_3$; SO_2CH_3 , SO_2CF_3 , CN, $COOR^{14}$, NO_2 , $CONR^{17}R^{18}$; C_{1-6} -alkyl, branched or unbranched, saturated or

unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R^{14} is chosen from the group consisting of C_{1-6} -alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; $PO(O-C_{1-4}$ -alkyl)₂, $CO(OC_{1-5}$ -alkyl), $CONH-C_6H_4-(C_{1-3}$ -alkyl), $CO(C_{1-5}$ -alkyl), $CO-CHR^{17}-NHR^{18}$, $CO-C_6H_4-R^{15}$, where R^{15} is ortho- $OOCOC_{1-3}$ -alkyl or meta- or para- $CH_2N(R^{16})_2$ where R^{16} is C_{1-4} -alkyl or 4-morpholino, wherein in the radicals R^{14} , R^{15} and R^{16} the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R^{17} and R^{18} in each case independently of one another are chosen from H; C_{1-6} -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or

R^9 and R^{10} or R^{10} and R^{11} together form an OCH_2O , OCH_2CH_2O , $OCH=CH$, $CH=CHO$, $CH=C(CH_3)O$, $OC(CH_3)=CH$, $(CH_2)_4$ or $OCH=CHO$ ring,

with the proviso that if R^9 , R^{11} and R^{13} correspond to H and one of R^{10} or R^{12} corresponds to H and the other corresponds to OCH_3 , X may not be OH, and

wherein group (ii) consists of an anti-muscarine agent selected from the group consisting of atropine, oxybutinin, propiverine, propantheline, emepronium, trospium, tolterodine, darifenacin and α,α -diphenylacetic acid 4-(N-methylpiperidyl) ester, duloxetine, imipramine and desmopressin, or a salt of any of the foregoing with a physiologically tolerated acid.

38. (previously presented) The composition of matter of claim 37, wherein one or more of said at least one compound selected from group (i) and at least one

compound selected from group (ii) is present in the form of a free base.

39. (previously presented) The composition of matter of claim 37, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a pure enantiomer or pure diastereoisomer.

40. (previously presented) The composition of matter of claim 37, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a mixture of stereoisomers.

41. (previously presented) The composition of matter of claim 40, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a racemic mixture.

42-43. (canceled)

44. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group a) consisting of tramadol, (+)-O-demethyltramadol and (+)-O-demethyl-N-mono-demethyl-tramadol.

45. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is (+)-tramadol.

46. (currently amended) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group b)

consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (~~meperidine~~)
- tilidine
- viminol
- butorphanol
- dezocine
- nalorphine
- pentazocine, and
- buprenorphine.

47. (previously presented) The composition of matter of claim 46, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- meptazinol
- nalbuphine
- tilidine, and
- buprenorphine.

48. (currently amended) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of

compounds corresponding to formula I wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH₃ and H,

R¹ is chosen from C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched;

R² and R³ independently of one another are chosen from the group consisting of H, and C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; or

R² and R³ together form a C₅₋₆-cycloalkyl radical, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

R⁹ to R¹³ are independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃ and C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H; or

R¹² and R¹¹ form a 3,4-OCH=CH ring, or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from the group consisting of Cl, F, OH, CF₂H, CF₃, OR¹⁴ and SR¹⁴, or

if R⁹ and R¹³ correspond to H, and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F, or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is chosen from CF₃, CF₂H, Cl or F, or

if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is chosen from the group consisting of OH, OC₂H₅ and OC₃H₇.

49. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein X is chosen from the group consisting of OH, F, OC(O)CH₃ and H.

50. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R^1 is CH_3 , C_2H_5 , C_4H_9 or t-butyl.


51. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R^2 and R^3 independently of one another are chosen from the group consisting of H, CH_3 , C_2H_5 , i-propyl and t-butyl.

52. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R^2 and R^3 together form a C_{5-6} -cycloalkyl radical which is saturated and unsubstituted.

53. (previously presented) The composition of matter of claim 52, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R^2 and R^3 together form a cyclohexyl group.

54. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R^9 to R^{13} independently of one another are chosen from the group consisting of H, Cl, F, OH, CF_2H , CF_3 , OCH_3 and SCH_3 ; with the proviso that 3 or 4 of the radicals R^9 to R^{13} must correspond to H.

55. (previously presented) The composition of matter of claim 48, wherein compounds corresponding to formula I where $R^3 = H$ are in the form of diastereomers corresponding to formula Ia



and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer, or are provided as a pure diastereomer, or compounds corresponding to formula I are provided in the form of the (+)-enantiomer.

56. (previously presented) The composition of matter of claim 48, wherein compounds corresponding to formula I, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided as the pure (+)-enantiomer.

57. (previously presented) The composition of matter of claim 48, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (2RS,3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
- (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3,4-dichlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3-difluoromethyl-phenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-1-dimethylamino-2-methyl-3-(3-methylsulfanyl-phenyl)-pentan-3-ol,
- (3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-4,4-dimethyl-pentan-3-ol,
- (2RS,3RS)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,

- (1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
 - (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
 - (+)-(1R,2R)-acetic acid 3-dimethylamino-1-ethyl-1-(3-methoxy-phenyl)-2-methyl-propyl ester,
 - (1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-1-(3-methoxy-phenyl)-propan-1-ol,
 - (2RS,3RS)-3-(4-chlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
 - (+)-(2R,3R)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
 - (2RS,3RS)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol, and
 - (+)-(2R,3R)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol,
- and hydrochloride salts of the foregoing.

58. (previously presented) The composition of matter of claim 37, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula II wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH₃ and H,

R¹ is C₁₋₄-alkyl, CF₃, OH, O-C₁₋₄-alkyl, Cl or F,

R⁹ to R¹³ independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃ and C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ or SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H; or

R¹² and R¹¹ form a 3,4-OCH=CH ring, or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is chosen from the group consisting of Cl, F, OH, CF₂H, CF₃, OR¹⁴ and SR¹⁴, or

if R⁹ and R¹³ correspond to H, and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F, or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is CF₃, CF₂H, Cl or F, or

if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is OH, OC₂H₅ or OC₃H₇.

59. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein X is OH, F or H.


60. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein R¹ is OH, CF₃ or CH₃.

61. (currently amended) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

R⁹ to R¹³ independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃, OCH₃ [[or]] and SCH₃, with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H, or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is OH, CF₂H, OR¹⁴ or SCH₃.

62. (previously presented) The composition of matter of claim 58, wherein the compounds corresponding to formula II are in the form of diastereomers corresponding to formula IIa



IIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer, or are provided as a pure diastereomer, or compounds corresponding to formula II are provided in the form of the (+)-enantiomer.

63. (previously presented) The composition of matter of claim 58, wherein compounds corresponding to formula II are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

64. (previously presented) The composition of matter of claim 58, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol,
- (1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,2R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methyl-cyclohexyl)-phenol, and
- (1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethyl-cyclohexyl)-phenol,

and hydrochloride salts of the foregoing.

65. (previously presented) The composition of matter of claim 37, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula III wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH₃ and H,

R⁹ to R¹³ independently of one another are chosen from the group consisting of H, Cl, F, OH, CF₂H, CF₃, C₁₋₄-alkyl, saturated and unsubstituted, branched or unbranched; OR¹⁴ and SR¹⁴, where R¹⁴ is chosen from C₁₋₃-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R⁹ to R¹³ must correspond to H; or

R¹² and R¹¹ form a 3,4-OCH=CH ring, or

if R⁹, R¹¹ and R¹³ correspond to H, one of R¹⁰ or R¹² also corresponds to H while the other is Cl, F, OH, SH, CF₂H, CF₃, OR¹⁴ or SR¹⁴, or

if R⁹ and R¹³ correspond to H and R¹¹ corresponds to OH, OCH₃, Cl or F, one of R¹⁰ or R¹² also corresponds to H while the other corresponds to OH, OCH₃, Cl or F, or

if R⁹, R¹⁰, R¹² and R¹³ correspond to H, R¹¹ is CF₃, CF₂H, Cl or F, or


if R¹⁰, R¹¹ and R¹² correspond to H, one of R⁹ or R¹³ also corresponds to H while the other is OH, OC₂H₅ or OC₃H₇.

66. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein X is OH, F or H.

67. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein:

R^9 to R^{13} independently of one another are chosen from the group consisting of H, Cl, F, OH, CF_2H , CF_3 , OCH_3 and SCH_3 , with the proviso that 3 or 4 of the radicals R^9 to R^{13} must correspond to H; or
if R^9 , R^{11} and R^{13} correspond to H, one of R^{10} or R^{12} also corresponds to H while the other is OH, CF_2H , OR^{14} or SCH_3 .

68. (previously presented) The composition of matter of claim 65, wherein the compounds corresponding to formula III are in the form of diastereomers corresponding to formula IIIa



IIIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer, or
are provided as a pure diastereomer, or
compounds corresponding to formula III are provided in the form of the (+)-enantiomer.

69. (previously presented) The composition of matter of claim 65, wherein compounds corresponding to formula III, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

70. (previously presented) The composition of matter of claim 65, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (+)-(1R,2R)-3-(2-dimethylaminomethyl-1-fluoro-cyclohexyl)-phenol,
 - (+)-(1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
 - (1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
 - (-)-(1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
 - (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
 - (-)-(1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, and
 - (1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine,
- and hydrochloride salts of the foregoing.

71. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (ii) is selected from the group consisting of: darifenacin, duloxetine, oxybutinin and tolterodine.

72. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (ii) is selected from the group consisting of: oxybutinin and tolterodine.

73. (previously presented) A pharmaceutical formulation comprising as an active compound combination a composition of matter according to claim 37 and at least one pharmaceutically suitable additive or auxiliary substance.